Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers

DSpace/Manakin Repository

Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers

Citable link to this page

 

 
Title: Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers
Author: Misale, Sandra; Bozic, Ivana; Tong, Jingshan; Peraza-Penton, Ashley; Lallo, Alice; Baldi, Federica; Lin, Kevin H.; Truini, Mauro; Trusolino, Livio; Bertotti, Andrea; Di Nicolantonio, Federica; Nowak, Martin A.; Zhang, Lin; Wood, Kris C.; Bardelli, Alberto

Note: Order does not necessarily reflect citation order of authors.

Citation: Misale, S., I. Bozic, J. Tong, A. Peraza-Penton, A. Lallo, F. Baldi, K. H. Lin, et al. 2015. “Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers.” Nature Communications 6 (1): 8305. doi:10.1038/ncomms9305. http://dx.doi.org/10.1038/ncomms9305.
Full Text & Related Files:
Abstract: Molecular targeted drugs are clinically effective anti-cancer therapies. However, tumours treated with single agents usually develop resistance. Here we use colorectal cancer (CRC) as a model to study how the acquisition of resistance to EGFR-targeted therapies can be restrained. Pathway-oriented genetic screens reveal that CRC cells escape from EGFR blockade by downstream activation of RAS-MEK signalling. Following treatment of CRC cells with anti-EGFR, anti-MEK or the combination of the two drugs, we find that EGFR blockade alone triggers acquired resistance in weeks, while combinatorial treatment does not induce resistance. In patient-derived xenografts, EGFR-MEK combination prevents the development of resistance. We employ mathematical modelling to provide a quantitative understanding of the dynamics of response and resistance to these single and combination therapies. Mechanistically, we find that the EGFR-MEK Combo blockade triggers Bcl-2 and Mcl-1 downregulation and initiates apoptosis. These results provide the rationale for clinical trials aimed at preventing rather than intercepting resistance.
Published Version: doi:10.1038/ncomms9305
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4595628/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:23473840
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters